Login to Your Account


Proteus Digital Health Inc. and Otsuka Pharmaceutical Co. Ltd. have received FDA approval to market what they call 'digital pill' technology to treat mental health disorders.

While there are important similarities, the U.S. Senate and the House of Representatives have taken different approaches to several matters in their respective tax reform proposals, including the tax credit for clinical studies of orphan drugs.

If it stands up against promised challenges, a new payment rule that would let the Centers for Medicare & Medicaid Services (CMS) cash in on some of the outpatient drug savings U.S. hospitals get through the 340B discount program could deepen the pricing rift between hospital groups and the biopharma industry.

More U.S. Headlines

Cast Your Vote

Should there be restrictions on the use of gene-editing technology?: